Since the bull market began on March 9, 2009, the Nasdaq is up 346%. That’s more than 50% better than the S&P’s return over the period.
And it’s all because of the new Convergence Economy we’ve been talking about here for some time now. These days, every business is a tech business, meaning the sector will beat the overall market for years to come.
Having said that, however, it bears noting that no stock, sector, or market rises in a straight line forever. Sooner or later, the market will lose steam.
Let me be clear. I see plenty of upside ahead through the end of 2017. And it bears repeating this is not the time to horde cash and hope for better prices.
Instead, you want to be in tech stocks. And if you use these three Gut Check Tools, you can invest with confidence – and protect your market-crushing gains.
There’s not a major sports league in the world today that wouldn’t love to undergo 138% growth in just four years.
We’re talking a total of 238 million viewers around the world for a “sport” that didn’t really hit its stride until 2010.
To cash in on this fast-growing trend, a group of owners from the National Football League, National Basketball Association, and Major League Baseball recently invested more than $140 million to start their own teams.
And if the players look more like computer geeks than athletes, it’s because that’s just what they are. In the new field of eSports, teams duel it out over computer games while fans watch online or at major arenas.
Here’s the thing. Though the field is new, it’s already ripe for disruption due to the immersive experience of virtual reality (VR).
Today, I’m going to reveal a VR firm that offers us a rare Convergence Economy play on the emerging lucrative mix of sports and digital tech.
The treatment that makes up 90% of the pharmaceutical market – good, old-fashioned small molecules created in the laboratory – isn’t going anywhere.
Yes, incredibly innovative treatments like T-cell therapy, microbiome therapies, and CRISPR gene editing are all having a huge impact on healthcare.
But we use small, synthetic molecules to create everything from aspirin and corticosteroids to sofosbuvir (Sovaldi) and ivacaftor (Kalydeco) – and we’ll keep doing so for a long time to come.
The small molecule technique dates back to the 1890s, but that doesn’t mean innovation cannot happen within that field. Scientists are hard at work in the labs, creating cutting-edge drugs, often tailored to treat a very specific disease or subset of patients.
Meanwhile, I’ve turned up a small British company that’s using its artificial intelligence platform to discover promising small molecule treatments faster – and cheaper – than ever before.
I call it biointelligence.
It’s a perfect illustration of the “Convergence Economy” we talk so much about here. By combining two or more fields of tech – in this case biotech and AI – it’s like a formula in which 1 + 1 = 3… and often a lot more that.
Today, we’re going to learn all about this tiny company and its brand-new biointelligence technology.
This company is privately held – so if you ask, Wall Street will say you can’t invest in it.
But I’ve a way you can.
In fact, I’ve found two ways.
Both of them will lead you to outsized returns – and hefty dividends.
At the time, it looked like Hillary Clinton would soon enter in the White House and clamp down on drug prices – and so the biopharmaceutical sector was deeply out of favor.
Turns out, however, our crazy bet paid off.
Despite his campaign rhetoric, President Donald Trump has pulled back from his own fiery rhetoric about drug-price caps.
That helped pushed biotech and drug stocks into a big uptrend.
And my paid-up members made peak gains of 116% – in just over eight months.
Today, things have changed – and investing in biopharma stocks is generally seen as a smart move. However, that means a lot of these shares have been bid up, and your best move is to buy big winners at deep discounts.
But to do that, you have to know how to find those deals.
Today I’ll show you how you can, too.
And I’ll reveal the three best Biotech Bargains out there right now
If you think China‘s tech sector is all about playing copycat, think again.
The United States has fallen behind in a key field after leading for It lies at the heart of such cutting technologies as Artificial Intelligence, machine learning, Big Data, even cracking the mysteries of the universe.
Of course, I’m talking about supercomputing. You see, China unveiled the world’s fastest computing last year. And in a slap in the face for Silicon Valley, did so without U.S. chips.
That’s why on June 14, the U.S. Department of Energy (DoE) said it will provide a three-year, 258 million grant to six American tech leaders. The goal is simple: reclaim the top spot from China.
Doing so includes not just computing, but advances in the brains that runs these machines and semiconductors.
Oakland, Calif. – Now that I’m on my way home from the Fourth Annual Cannabis Business Summit & Expo, there’s one statistic I just can’t stop thinking about.
And that’s a big deal.
You see, people throw around a ton of numbers at these conferences. But their true values can be incredibly opaque.
Whether the data you pick up on the Expo floor is from an entrepreneur, a lobbyist, a politician, an investment analyst, a researcher, a salesperson, or even a “brand representative,” you’ve got to do some work with it.
You’ve got to put it under the microscope, turn it around in your head, and figure out what it truly means. While most of the “tips” you get are just noise, many are interesting enough to share with friends.
But only a very, very few are truly valuable.
I’m talking about a number or statistic that flips a switch in your brain – and points your way toward future profits in your investment portfolio.
And the one number that stuck with me is this – 25%.